|
Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 14, Num. 1, 1997, pp. 53-55
|
Biotecnologia Aplicada 1997 Volume 14 No. 1, pp.53-55
THE HUMORAL IMMUNE RESPONSE OF RABBITS AND MICE AGAINST MULTI-EPITOPE
POLYPEPTIDES ARRYING DIFFERENT V3 REGIONS OF HIV-1
Diogenes Quintana,^1 Carmen Gomez,^1 Emilio Carpio,^1 Enrique Iglesias^2
and Carlos Duarte^2
^1Center for Genetic Engineering and Biotechnology, Sancti Spiritus.
^2AIDS, Department, Vaccine Division, Center for Genetic Engineering and
Biotechnology, P.O. Box 6162, Havana City, Cuba.
E- mail: carlos.duarte@cigb.edu.cuIntroduction
Code Number:BA97016
Size of Files:
Text: 12.7K
Graphics: No associated graphics files
The V3 loop of the gp120 contains the Principal Neutralizing Domain of
HIV-1 (1). Passive transfer of monoclonal antibodies (MAbs) against this
region protects chimpanzees and SCID mice from viral challenge (2, 3), and
correlates with protection in immunized chimpanzees (4), suggesting that
they may be important to confer protection in humans. We have constructed
eleven different variants of multi-epitope polypeptides (MEPs) expressing
the V3 region from different HIV-1 isolates, as a novel approach to induce
a broadly reactive antibody response against a variable region (5, 6). In
this presentation we present comparative data on the humoral immune
response against two of these proteins: MEPs TAB9 and TAB13. The
differences in the immunodominance of the V3 epitopes in rabbit and mice is
also highlighted.
Materials and Methods
A DNA fragment encoding for 15 amino acids regions of the V3 loop from HIV-
1 isolates LR150, JY1, MN, RF, BRVA, and LAI was previously synthesized and
cloned fused to the amino terminal fragment of the human IL2 in the plasmid
named pTab4 (6). The V3 regions are linked by the spacer AGGGA. The V3
regions included in TAB4 were selected from the V3 sequences reported by La
Rosa, et al. (7) according to two basic criteria: (a) the fifteen
amino acid central region of V3 contains the neutralizing epitopes. (b) two
isolates will group together if they share at least 7 straight amino
acid.
The central tetrapeptide of the V3 loop is the more conserved sequence in
this region and forms a type II Beta turn. Five of the selected V3 regions
contains the central motive GPGR, which is typical for the subtype B
circulating meanly in Europe and the Americas. The other region (JY1)
contains the motive GLGQ which has been reported in viruses from subtype D,
circulating in Africa and Asia (Table 1).
---------------------------------------------------------------------------
Table 1. V3 epitopes included in MEPs.
---------------------------------------------------------------------------
Strain Sequence Clade
LR150 SRGIRIGPGRAILAT B
BRVA RKRITMGPGRVYYTT B
RF RKSITKGPGRVIYAT B
IIIB SIRIQRGPGRAFVTI B
JY1 RQSTPIGLGQALYTT D
MN RKRIHIGPGRAFYTT B
C4-11 TSITIGPGQVFYRTG
C4-13 RQRTSIGQGQALYTT
---------------------------------------------------------------------------
The IL2 coding region in pTab4 was then replaced by a DNA fragment encoding
for the 44 amino acid amino terminal part of the P64K protein of
Neisseria meningitidis. The resulting plasmid was named pTab9 and
encodes for a fusion protein of 17 kD that was called TAB9. TAB13
was derived from TAB9 through the insertion of two additional V3 regions,
C4-11 and C4-13 before the C terminal epitope (LAI), and has a molecular
weigh of 20 kD.
Both proteins were expressed as inclusion bodies in Escherichia
coli, readily purified and administered to mice and rabbits using
different adyuvants. The MEP format was compared with the more classical
approach of chemical conjugation by immunising mice with TAB9 and a mixture
of the six V3 synthetic peptides coupled to bovine seroalbumin (BSA).
Results and Discussion
MEP TAB9 was more immunogenic in mice than BSA conjugated
peptides
First we compared the immune response of Balb/C mice against TAB9 and a
mixture of V3 synthetic peptides coupled to BSA. The amount of TAB9 and
BSA-V3 peptides were adjusted to approximately the same nolarity of V3
epitopes. Specific antibodies against proteins and V3 peptides were
measured by an indirect ELISA. After two intraperitoneal (IP) injections in
Freund's Complete Adjuvant a strong positive signal against JY1 was
observed in the TAB9 group, together with a weak but positive reaction
against peptides BRVA and MN. In contrast no response against any of these
peptides was observed in the V3-BSA immunized group. The rest of the
peptides tested (LAI, LR150 and RF) were immunosilent in both
immunogens.
To explain this experimental observations we can advanced three
possibilities: (a) the P64 moiety in TAB9 provided more efficient T cell
help than BSA, (b) the linkage of the six V3 regions in the same molecule
provide efficient T cell help among each other, (c) the antibody response
is diverted by immunodominant and more abundant B cell epitopes in the
BSA.
Immunodominance among V3 regions and the influence of the H-2
haplotype
To investigate the influence of the H-2 haplotype in the antibody response
against TAB9 and the V3 regions we immunized mice from three different
haplotypes. Haplotype H2d, which includes Balb/C, showed a pattern of
reactivity similar to the one described. However, mice from haplotypes H-2k
of H-2b essentially do not respond to any of the V3 peptides or even
against TAB9. In the few sera where some response could be detected these
were also directed against JY1, LR150 or MN.
Since our main goal is to generated a wide antibody response against V3
from different HIV-1 subgroups, the relationship of immunodominance among
V3 peptides having different but related amino acid sequence is of primary
importance. From the experiments done in mice it was clear that the
immunodominance of V3 regions follows the order: JY1>MN, BRVA >LAI,
LR150, RF. The three last regions were practically immunosilent in our
experiments.
Taking into consideration these results, we hypothesized that the
regulation of the immunological repertoire in mice account for the
restriction of the antibody response to certain V3 sequences. Looking for
patterns of homology we made the interesting observation that the GPG
sequence was present five times, regularly spaced along the V Beta chains
of the TCR in mice. We had previously shown that JY1 peptide, the more
immunogenic region in TAB9, is the only one which lack the motif GPG in the
central part of the loop. This findings lead us to propose that B cells
expressing surface receptors for this motif are submitted to a more
rigorous control by the idiotipic network in mice.
In the rabbit model, where the V3 region is more immunogenic, both MEPs
elicited high antibody titers against the protein. Additionally this
response in rabbits was more evenly distributed among V3 peptides. Some of
these sera also showed neutralizing activity against HIV-1 laboratory
isolates. These results confirm that the animal species have a major
influence in the antibody response against V3.
Comparison of the immunogenicity of TAB9 and TAB13
Previous studies in rabbits of the immunogenicity of other MEPs containing
the same six V3 regions showed a high degree of cross-reactivity against V3
peptides with the central regions GPGR or GLGQ, homologous to those present
in the immunogen. However 1 or 2 orders lower antibody titers were found
against other peptides with the central region GQGR and GQGQ circulating in
Africa and Asia. We incorporated these peptides in TAB13 to generated a
stronger antibody reponse against these sequences.
However, when the immunogenicity of TAB9 and TAB13 was compared we found
that the geometric mean of the antibody titers against protein was one
order of magnitude higher in mice immunized twice with 10 ug of TAB9 than
in mice immunized with four different batches of TAB13. Interestingly,
equivalent titers were observed when the amount of TAB13 was doubled up to
20 ug. When we next looked at the time course of the antibody response
against the proteins in rabbits we found a similar effect.
Finally, either the geometric mean of the antibody titers against peptides
or the frequency of response against V3 peptides were significantly higher
for the TAB9 group compared with TAB13. Even antibody titers against
peptides C4-11 and C4-13, that are present only in TAB13, did not increase
when this protein was used as immunogen (Table 2).
---------------------------------------------------------------------------
Table 2. Antibody responses against V3 in rabbits immunized with
TAB9 and TAB13.
---------------------------------------------------------------------------
Immun- LR150 JY1 RF MN BRVA IIIB G F C4-11 C4-13
ogens
---------------------------------------------------------------------------
TAB9 51200 204800 102400 204800 51200 102400 102400 51200 6400
25600 25600 6400 102400 6400 102400 25600 <100 <100
1600 51200 12800 6400 3200 400 4525 3200 6400
204800 12800 51200 102400 204800 6400 51200 3200 102400
---------------------------------------------------------------------------
G 25600 43054 25600 60887 21527 12800 27917 100 8063 16127
---------------------------------------------------------------------------
TAB13 <100 12800 <100 3200 12800 3200 6400 6400 <100
25600 204800 51200 102400 51200 12800 51200 51200 6400
25600 6400 <100 3200 <100 <100 8063 <100 <100
1600 6400 400 6400 <100 12800 3200 6400 <100
---------------------------------------------------------------------------
G 10159 18102 4525 9051 25600 8063 10973 75 12800 6400
---------------------------------------------------------------------------
G: Geometric mean of antibody titers.
F:Frequency of respone against V3 peptides.
--------------------------------------------------------------------------
From this set of experiments we concluded that the inclusion of two V3
regions reduced the inununogenicity of the MEP in mice and rabbits.
As the molecular weight of TABI3 is only 1.2 times higher than TAB9 we do
not consider that the corresponding differences in the number of molecules
from each proteins were relevant for the immunogenicity. Another
explanation that could be advanced is the existence of a differential
surface exposare of the V3 epitopes between MEPs. To address this problem
we analysed the binding of equimolar mounts of both proteins in a two site
sandwich ELISA using specific MAbs.
Four MAbs against the V3 regions/MN, LAI and JYI were used as capture
antibody. HRP-conjugated MAb 448, directed against the p64K N terminal
fragment was used as second antibody. From this experiment we concluded
that the average of the absorbance values for 10 replicated samples were
always significantly higher for TAB9. These differences, although
moderate, were consistent in several experiments indicating a preferential
surface exposition of the V3 epitopes in TAB9. It seems hard to conclude
that these modest differences are the responsible for the reduced
hmnunogenicity of TAB 13 but it is attractive to thhhk that it could at
least influence on it. It is possible to speculate that as the molecular
weight increase the intramolecular interactions augments, and the protein
acquired a more complex folding pattern and globular structure affecting
the accessibility of the V3 regions and therefore the immunogenicity.
If the numnber of V3 to be included in a MEP is limited by these adverse
effects it would be necessary the adequate selection of the V3 sequence to
be include in the MEP in order to cover as many HIV-I variants as possible.
An alternative approach could be the design of immnunogens by geographic
area based on the data of the molecular epidemiology of HIV-I and
specifically the V3 region.
Copyright 1997 Elfos Scientiae
|